Lifesci Capital Estimates Upstream Bio FY2025 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Investment analysts at Lifesci Capital issued their FY2025 earnings estimates for shares of Upstream Bio in a research report issued to clients and investors on Tuesday, December 2nd. Lifesci Capital analyst K. Dellorusso expects that the company will post earnings of ($2.55) per share for the year. Lifesci Capital currently has a “Outperform” rating and a $43.00 target price on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. Lifesci Capital also issued estimates for Upstream Bio’s Q4 2025 earnings at ($0.67) EPS.

UPB has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, October 8th. Truist Financial initiated coverage on Upstream Bio in a research note on Tuesday, October 14th. They set a “buy” rating and a $47.00 target price for the company. Finally, Evercore ISI started coverage on Upstream Bio in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.33.

Upstream Bio Price Performance

Upstream Bio stock opened at $26.97 on Thursday. The firm has a 50 day simple moving average of $22.96 and a 200-day simple moving average of $16.95. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -14.35 and a beta of 1.83. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.00.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The firm had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.65 million.

Institutional Investors Weigh In On Upstream Bio

Several institutional investors and hedge funds have recently modified their holdings of UPB. Vanguard Group Inc. grew its position in Upstream Bio by 12.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after acquiring an additional 271,718 shares in the last quarter. Bain Capital Life Sciences Investors LLC grew its stake in Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after purchasing an additional 144,216 shares in the last quarter. Norges Bank acquired a new position in Upstream Bio during the 2nd quarter worth $10,650,000. Marshall Wace LLP increased its holdings in Upstream Bio by 198.8% during the 3rd quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock worth $16,327,000 after purchasing an additional 577,473 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in Upstream Bio by 17.9% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 843,502 shares of the company’s stock valued at $15,866,000 after purchasing an additional 127,998 shares in the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.